Skip to main content
Premium Trial:

Request an Annual Quote

Innogenetics' Nine-month Revenues Increase 6 Percent; Solvay's Stake at 95 Percent

NEW YORK (GenomeWeb News) – Innogenetics today said that its revenues for the first nine months of 2008 increased around 6 percent to €43.1 million ($54.9 million) from €40.8 million year over year.
The molecular diagnostics firm, which is in the process of being acquired by Solvay Pharmaceuticals, said that its diagnostics revenues increased around 6 percent for the first nine months of the year, though they decreased by nearly the same amount for the third quarter. It said that diagnostic products sales have been driven primarily by tests for infectious diseases, Alzheimer’s disease, and genetic conditions. The firm said that it “continues to feel competitive pressure in the area of HLA tissue typing.”
Innogenetics reported an operating loss of €23 million for the nine-month period, due partly to €18.1 million in non-recurring restructuring and impairment losses.
Innogenetics noted that its shares are expected to be delisted on Dec. 12 from the Euronext Brussels exchange. Shareholders have tendered 95.33 percent of Innogenetics’ shares to Solvay, which outbid Gen-Probe with a €200.7 million offer for 100 percent of Innogenetics’ outstanding shares.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.